Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

COYA

Coya Therapeutics Inc

May 03 • 04:00PM ET

8.68

Dollar change -0.10
Percentage change -1.14	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF IWC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.84	Insider Own	13.90%	Shs Outstand	14.41M	Perf Week	0.93%
Market Cap	126.21M	Forward P/E	-	EPS next Y	-1.50	Insider Trans	0.05%	Shs Float	12.52M	Perf Month	-5.24%
Income	-7.99M	PEG	-	EPS next Q	-0.30	Inst Own	20.16%	Short Float	1.47%	Perf Quarter	42.53%
Sales	6.00M	P/S	21.03	EPS this Y	-34.81%	Inst Trans	-	Short Ratio	1.84	Perf Half Y	87.07%
Book/sh	2.47	P/B	3.51	EPS next Y	-40.85%	ROA	-32.16%	Short Interest	0.18M	Perf Year	78.97%
Cash/sh	2.24	P/C	3.87	EPS next 5Y	-	ROE	-58.62%	52W Range	3.21 - 10.69	Perf YTD	17.14%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-22.41%	52W High	-18.80%	Beta	1.09
Dividend TTM	-	Quick Ratio	8.15	Sales past 5Y	0.00%	Gross Margin	99.54%	52W Low	170.40%	ATR (14)	0.62
Dividend Ex-Date	-	Current Ratio	8.15	EPS Y/Y TTM	-	Oper. Margin	-122.62%	RSI (14)	48.85	Volatility	6.46% 7.31%
Employees	8	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-133.08%	Recom	1.00	Target Price	14.50
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	128.14%	Payout	-	Rel Volume	0.39	Prev Close	8.78
Sales Surprise	-19.97%	EPS Surprise	-45.59%	Sales Q/Q	-	Earnings	Mar 19 BMO	Avg Volume	100.07K	Price	8.68
SMA20	0.06%	SMA50	-5.65%	SMA200	39.43%	Trades		Volume	39,361	Change	-1.14%

Apr-26-24 08:15AM	Coya Therapeutics Presents Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium (Business Wire)
Apr-22-24 08:15AM	Coya Therapeutics to Participate in the Mizuho Neuroscience Summit (Business Wire)
Apr-18-24 08:15AM	Coya Therapeutics to Participate in the 3rd Annual ALS Drug Development Summit (Business Wire)
Apr-08-24 08:15AM	Coya Therapeutics Scientific Advisory Board Chairman Dr. Stanley Appel to Present Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium (Business Wire)
Mar-21-24 05:31AM	Coya Therapeutics Inc (COYA) Reports Fiscal 2023 Financial Results and Corporate Updates (GuruFocus.com)
09:53PM	Loading…
Mar-19-24 09:53PM	COYA Stock Earnings: Coya Therapeutics Reported Results for Q4 2023 (InvestorPlace)
08:15AM	Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial Results (Business Wire)
Mar-12-24 09:00AM	Coya Therapeutics to Participate in BTIG Fireside Discussion (Business Wire) -7.68%
08:00AM	Coya Therapeutics Presents ALS Biomarker Data at Society of Neuroimmune Pharmacology Conference (Business Wire)
Mar-06-24 08:15AM	Coya Therapeutics Presents Biomarker Data on Neuroinflammatory Pathways in Frontotemporal Dementia (FTD) at the AD/PD 2024 Conference (Business Wire)
Feb-29-24 08:15AM	Coya Therapeutics to Present Data on Immune System and Regulatory T Cell (Treg) Contributions in Frontotemporal Dementia (FTD) Patients at AD/PD 2024 Conference (Business Wire) -5.86%
Feb-22-24 08:15AM	Coya Therapeutics to Present Novel Biomarker Survival Data in Large Cohort of ALS (Amyotrophic Lateral Sclerosis) Patients at Society of Neuroimmune Pharmacology Conference (Business Wire)
Feb-21-24 08:15AM	Coya Therapeutics Issues Letter to Stockholders Highlighting Expansion of COYA 302 into Alzheimers Disease and Coyas Pathway to a Pipeline in a Product (Business Wire) +7.94%
Feb-13-24 08:15AM	Coya Therapeutics Licenses Intellectual Property Rights for Use of Next Generation Immune Modulatory Biologics in Combination with COYA 301 to Enhance Regulatory T Cells (Tregs) in Inflammatory Diseases (Business Wire)
Jan-29-24 08:15AM	Coya Therapeutics SAB Chairman Dr. Stanley Appel, M.D. Selected as Speaker at the Society of Neuroimmune Pharmacology Conference (Business Wire)
08:15AM	Loading…
Jan-18-24 08:15AM	Coya Therapeutics to Participate in Upcoming Chardan Biotech Leadership Call Series (Business Wire)
Jan-16-24 08:15AM	Coya Therapeutics Announces Pipeline Expansion of COYA 302 to Include Frontotemporal Dementia and Parkinsons Disease in Addition to Amyotrophic Lateral Sclerosis (Business Wire) -10.27%
03:59AM	DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing (PR Newswire)
Jan-05-24 08:00AM	Coya Therapeutics Announces Successful Pre-IND and Type C Meetings with the FDA to Advance the Development of COYA 302 for Treatment of Amyotrophic Lateral Sclerosis (ALS) (Business Wire)
Dec-20-23 08:30AM	Mr. Wilbur L. Ross, Former United States Secretary of Commerce, Joins Board of Coya Therapeutics, Inc. (Business Wire) -7.66%
Dec-14-23 03:54PM	David Einhorn's Greenlight Capital Boosts Coya Therapeutics Holding (GuruFocus.com)
03:54PM	David Einhorn's Greenlight Capital Adds Coya Therapeutics to Its Portfolio (GuruFocus.com)
Dec-13-23 08:00AM	Coya Therapeutics CEO Dr. Howard Bermans Letter to Stockholders (Business Wire)
Dec-12-23 08:00AM	Coya Therapeutics Announces Closing of $26.5 Million Private Placement (Business Wire)
Dec-06-23 07:05AM	Coya Therapeutics Announces $26.5 Million Private Placement (Business Wire)
07:00AM	Coya Therapeutics, Inc. and Dr. Reddys Laboratories Enter into an Exclusive Collaboration for Development and Commercialization of COYA 302, an Investigational Combination Therapy for Treatment of Amyotrophic Lateral Sclerosis (ALS) (Business Wire)
Nov-08-23 09:00AM	Coya Therapeutics, Inc. Provides Business Update and Reports Q3 2023 Unaudited Financial Results (Business Wire)
Oct-27-23 09:00AM	Coya Announces Acceptance of Oral Presentation, Regulatory T Cell Expansion Strategy to Target Inflammation in Alzheimers Disease: A Phase 1 Feasibility Study, at the 18th International Conference on Alzheimers and Parkinsons Disease in Lisbon (Business Wire)
Oct-09-23 08:00AM	Coya Therapeutics (Coya) Announces Completion of Enrollment in a Well-Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimers Disease (AD) (Business Wire)
Oct-05-23 09:00AM	Coya Therapeutics Presents New Experimental Data Supporting the Mechanism of Action of COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS) at the 22nd Annual Northeast ALS (NEALS) Consortium Meeting (Business Wire)
09:00AM	Loading…
Oct-03-23 09:00AM	Coya Therapeutics Announces the Presentation of Human Ex-Vivo Mechanistic Data Further Supporting the Development of COYA 302 for Amyotrophic Lateral Sclerosis (ALS) at the 22nd Annual Northeast ALS (NEALS) Consortium Meeting (Business Wire) -5.38%
Sep-27-23 09:00AM	Coya Therapeutics to Present at the LD Micro Investor Conference (Business Wire)
Sep-22-23 09:00AM	Coya Therapeutics Licenses Exclusive Worldwide rights to Exosome Engineering Technology (EET) from Carnegie Mellon University (CMU) (Business Wire)
Sep-07-23 09:15AM	Coya Therapeutics Successfully Engineers Regulatory T Cell (Treg) Derived Exosomes with CTLA-4 Protein to Selectively Target Immune Cells with Potential to Deliver Targeted Therapies Across Multiple Diseases (Business Wire) +12.12%
Aug-31-23 08:00AM	Coya Therapeutics Announces Publication of Potential Novel Blood Biomarker Data in Amyotrophic Lateral Sclerosis (ALS) Patients That Accurately Reflect Therapeutic Responses When Treated with Regulatory T Cell (Treg) Enhancing Therapies (Business Wire)
Aug-25-23 09:00AM	Coya Therapeutics To Present Novel Proof of Concept Exosome Modification Technology at the 5th Exosome Based Therapeutic Development Summit in Boston, MA on September 7, 2023 (Business Wire)
Aug-21-23 01:31PM	Headline (News Direct)
07:00AM	Former CEO and Chairman of the Board of Bayer Pharma AG, Dieter Weinand, Joins Coyas Board of Directors (Business Wire)
Aug-08-23 07:00AM	Coya Therapeutics, Inc. Provides Business Update and Reports Q2 2023 Unaudited Financial Results (Business Wire)
Aug-03-23 07:00AM	Coya Therapeutics to Present at the BTIG Virtual Biotechnology Conference 2023 (Business Wire)
Jul-19-23 07:00AM	Coya Therapeutics ("Coya") Announces the Appointment of Dr. Merit Cudkowicz, M.D., M.Sc., as Clinical Advisor to Support the Development of COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS) (Business Wire)
Jul-17-23 12:21PM	Coya Therapeutics' Alzheimer's Candidate Shows Lower Biomarker Levels Associated With Neuroinflammation (Benzinga) +5.99%
07:00AM	Coya Therapeutics Reports Additional Proof-of-Concept Clinical Biomarker Data in Patients with Alzheimers Disease (Business Wire)
Jul-05-23 08:30AM	Coya Therapeutics ("Coya") Appoints Industry and Drug Development Veteran, Dr. Fred Grossman, to President and Chief Medical Officer succeeding Dr. Adrian Hepner (Business Wire)
Jun-28-23 07:00AM	Coya Therapeutics to Present Proof-of-Concept Clinical Data for Low-Dose Interleukin-2 (ld IL-2) for the Treatment of Patients with Alzheimers Disease (AD) at the 2023 Alzheimers Association International Conference (AAIC) (Business Wire)
Jun-20-23 07:00AM	Coya Therapeutics, Inc. (Coya) Broadens its COYA 300 Biologics Patent Estate for the Exclusive Patent Rights and Know-how in treatment of Parkinson's Disease (PD) (Business Wire)
Jun-14-23 07:00AM	Coya Therapeutics Strengthens its Management Team with the Appointment of Dr. Michelle Frazier as Senior Vice President of Regulatory Affairs (Business Wire) -5.75%
Jun-12-23 07:00AM	Coya Therapeutics CEO Dr. Howard Bermans Letter to Stockholders (Business Wire)
Jun-07-23 07:00AM	Coya Therapeutics Reports Additional Blood Biomarker and Brain Imaging Data Showing Decrease in Neuroinflammation Following Treatment with COYA 301 in Alzheimers Disease (AD) (Business Wire) +8.29%
Jun-05-23 07:00AM	Coya Therapeutics Strengthens Scientific Advisory Board (SAB) with the Addition of Neuroimmunology Pioneer, Dr. Guillaume Dorothée, an Expert on the Role of the Immune System and Regulatory T Cells (Tregs) in Alzheimers Disease (AD) (Business Wire) -8.10%
May-22-23 07:00AM	Coya to Present Additional Biomarker and Brain Imaging Data for COYA 301 in Alzheimers Disease (AD) at the LD Micro Conference on June 7, 2023 (Business Wire)
May-16-23 02:42PM	Why Coya Therapeutics Shares Are Shooting Higher Today (Benzinga) +10.00%
08:50AM	Here's Why Momentum in Coya Therapeutics, Inc. (COYA) Should Keep going (Zacks)
07:00AM	Coya Therapeutics COYA 301 Increased Treg Function and Halted Cognitive Decline in an Open Label Study in Patients with Alzheimers Disease (Business Wire)
May-12-23 07:47AM	Is Coya Therapeutics (NASDAQ:COYA) In A Good Position To Invest In Growth? (Simply Wall St.)
May-10-23 07:00AM	Coya Therapeutics, Inc. Provides Business Update and Reports Q1 2023 Unaudited Financial Results (Business Wire)
May-09-23 07:15AM	Sidoti's Micro-Cap Virtual May Conference (ACCESSWIRE)
07:00AM	Coya Therapeutics, Inc. to Present at the Sidoti Virtual Investor Conference on Thursday, May 11, 2023, at 2:30pm ET (Business Wire)
May-02-23 03:30PM	Sidoti's Micro-Cap Virtual May Conference (ACCESSWIRE)
Apr-14-23 09:00AM	Alzheimers Disease Largely Remains A Mystery, With A Lack Of Highly Effective Treatments - Could Regulatory T-Cells (Tregs) Be The Answer? (ACCESSWIRE)
Mar-31-23 07:00AM	Coya Therapeutics to Present Biomarker and Preliminary Efficacy Clinical Data for COYA 301 for the Treatment of Patients with Alzheimers Disease (AD) at the 2023 Keystone Symposia Meeting for Neurodegeneration held on May 15-19th, 2023 (Business Wire)
Mar-29-23 04:01PM	Coya Therapeutics, Inc. Provides Business Update and Reports FY 2022 Unaudited Financial Results (Business Wire) +6.36%
09:00AM	There Is No Cure For ALS, But Coya Therapeutics Might Have The Answer According To A New Clinical Study (News Direct)
Mar-27-23 07:00AM	Coya Therapeutics Strengthens Leadership Team with Addition of Arun Swaminathan, Ph.D. as Chief Business Officer (Business Wire)
Mar-23-23 09:15AM	Coya Therapeutics Enters First-Of-Its-Kind Partnership With Multi-Billion Dollar Drug Company Why This Is a Major Moment For Drug Development (News Direct)
07:44AM	Coya Therapeutics, Inc. to Present at the Virtual Investor Summit on Wednesday, March 29, 2023, at 11:00am ET (Business Wire)
Mar-22-23 09:15AM	Coya Therapeutics COYA 302 Treating ALS Proves Effective In Proof-Of-Concept Academic Clinical Study (News Direct)
Mar-21-23 11:38AM	Coya Therapeutics Reveals Proof-of-Concept Data From Small Study With ALS Patients (Benzinga)
11:24AM	COYA, Dr. Reddy's Sign Deal for Proposed Abatacept Biosimilar (Zacks)
09:55AM	Houston-Based Coya Therapeutics Partners With Multi-Billion Dollar Global Drug Company Dr. Reddys Laboratories To License and Commercialize COYA 302 (News Direct)
07:50AM	Reminder: Coya Therapeutics to Host Conference Call Presenting Positive Clinical Data of COYA 302 in Patients with Amyotrophic Lateral Sclerosis (ALS) Today at 8:00am ET (Business Wire)
07:00AM	Coya Therapeutics, Inc. Announces Positive Results from a Proof-of-Concept Academic Clinical Study for COYA 302 in Amyotrophic Lateral Sclerosis (ALS) (Business Wire)
Mar-20-23 07:00AM	Coya Therapeutics, Inc. Announces an Agreement with Dr. Reddys Laboratories, Ltd. to License its proposed biosimilar Abatacept for the Development and Commercialization of COYA 302 for the Treatment of Neurodegenerative Diseases (Business Wire)
Mar-09-23 07:00AM	Coya Therapeutics to Host Conference Call Presenting Clinical Data of COYA 302 in Patients with Amyotrophic Lateral Sclerosis (ALS) on March 21, 2023, at 8:00am ET (Business Wire)
Mar-06-23 09:00AM	This Company Is Focused on Treg-Enhancing Therapies - Could This Be Medicines Next Frontier? (News Direct)
Feb-28-23 09:00AM	Houston-Based Coya Therapeutics To Present Results From ALS Clinical Study Data For Its Investigational Biologic Combination at the 2023 MDA Clinical & Scientific Conference in Dallas (News Direct) +6.17%
Feb-27-23 07:00AM	Coya Therapeutics to Present ALS Clinical Study Data for its Investigational Biologic Combination at the 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference. (Business Wire)
Feb-16-23 09:15AM	Coya Therapeutics Expansion Of Exclusive Worldwide Licensing Agreement With ARscience Biotherapeutics Could Have Outsized Impact On Neurodegenerative And Autoimmune Diseases Treatments (News Direct)
Feb-15-23 07:13AM	Coya Therapeutics, Inc. Announces Expansion of Exclusive Worldwide Licensing Agreement with ARScience Biotherapeutics, Inc. for Development and Commercialization of COYA 301, Coyas Low-Dose Interleukin 2 (IL-2) Product Candidate (Business Wire)
Feb-02-23 09:00AM	Coya Therapeutics, Inc. to Present Proof of Concept Clinical Data at Multiple Scientific Conferences Throughout 2023 (Business Wire)
Jan-26-23 09:01AM	Coya Therapeutics, Inc. Announces Preclinical Data Supporting the Role of Expanded Regulatory T Cells (Tregs) as Potential Disease-Modifying Treatment in an Animal Model of Alzheimers Disease (AD) (Business Wire)
Jan-03-23 04:15PM	Coya Therapeutics, Inc. Announces Closing of $15.25 Million Initial Public Offering (Business Wire)
Dec-29-22 11:20AM	Coya Therapeutics, Inc. Announces Pricing of $15.25 Million Initial Public Offering (Business Wire)

Coya Therapeutics, Inc. is a clinical-stage biotechnology company which engages in developing proprietary medicinal products to modulate the function of regulatory T cells. The company was founded by Howard Berman in 2020 and is headquartered in Houston, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lee Ann	Director	Aug 22 '23	Buy	3.62	1,000	3,620	17,479	Mar 05 08:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

COYA

Coya Therapeutics Inc

Upgrade your FINVIZ experience